Healthcare provider profile · identity verified

Chelukala Bapu Reddy, M.D.

Allopathic & Osteopathic Physicians|Internal Medicine · GRIFFIN, GA · NPI 1467549840

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Chelukala Bapu Reddy, M.D. received $86.43 in general payments during 2025 across 4 reported records.

AstraZeneca Pharmaceuticals LP accounted for 31.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 5 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Symbicort by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$86.43

4 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$27.10	31.4%	1	2025
Verona Pharma, Inc.	Unresolved — no canonical attribution shown	$21.08	24.4%	1	2025
GlaxoSmithKline, LLC.	Unresolved — no canonical attribution shown	$20.70	23.9%	1	2025
Amgen Inc.	Unresolved — no canonical attribution shown	$17.55	20.3%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$86.43	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
FARXIGA Normalized: farxiga	Drug	AstraZeneca Pharmaceuticals LP	$27.10	1	2025
Source payment records 2025-06-06 · AstraZeneca Pharmaceuticals LP · $27.10 · Open Payments source
Ohtuvayre Normalized: ohtuvayre	Drug	Verona Pharma, Inc.	$21.08	1	2025
Source payment records 2025-12-02 · Verona Pharma, Inc. · $21.08 · Open Payments source
TRELEGY ELLIPTA Normalized: trelegy ellipta	Drug	GlaxoSmithKline, LLC.	$20.70	1	2025
Source payment records 2025-02-03 · GlaxoSmithKline, LLC. · $20.70 · Open Payments source
OTEZLA Normalized: otezla	Drug	Amgen Inc.	$17.55	1	2025
Source payment records 2025-03-14 · Amgen Inc. · $17.55 · Open Payments source
REPATHA Normalized: repatha	Biological	Amgen Inc.	$17.55	1	2025
Source payment records 2025-03-14 · Amgen Inc. · $17.55 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
FARXIGA farxiga	2025	Farxiga	2024	155	exact normalized	Medicare Part D
TRELEGY ELLIPTA trelegy ellipta	2025	Trelegy Ellipta	2024	38 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	155	24
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	65	14
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	SHINGRIX open payments reported associated product	CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452	Shingrix · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	TRELEGY ELLIPTA open payments reported associated product	CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369	Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row	38	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	1639	186
Atorvastatin Calcium	Atorvastatin Calcium	1485	215
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	1213	149
Omeprazole	Omeprazole	1053	142
Gabapentin	Gabapentin	1011	85
Pravastatin Sodium	Pravastatin Sodium	985	44
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	941	114
Lisinopril	Lisinopril	865	119
Furosemide	Furosemide	725	104
Potassium Chloride	Potassium Chloride	660	92
Metformin Hcl	Metformin Hcl	609	92
Famotidine	Famotidine	586	37
Hydralazine Hcl	Hydralazine Hcl	584	82
Albuterol Sulfate Hfa	Albuterol Sulfate	570	121
Metoprolol Tartrate	Metoprolol Tartrate	510	58
Tamsulosin Hcl	Tamsulosin Hcl	480	57
Levothyroxine Sodium	Levothyroxine Sodium	469	55
Clonidine Hcl	Clonidine Hcl	453	77
Divalproex Sodium	Divalproex Sodium	370	suppressed
Carvedilol	Carvedilol	356	37
Eliquis	Apixaban	348	35
Losartan Potassium	Losartan Potassium	339	54
Clopidogrel	Clopidogrel Bisulfate	335	34
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	334	111
Levetiracetam	Levetiracetam	324	23
Pantoprazole Sodium	Pantoprazole Sodium	313	49
Donepezil Hcl	Donepezil Hcl	298	suppressed
Trazodone Hcl	Trazodone Hcl	289	31
Jardiance	Empagliflozin	276	32
Memantine Hcl	Memantine Hcl	273	suppressed
Mirtazapine	Mirtazapine	270	16
Clonazepam	Clonazepam	263	32
Allopurinol	Allopurinol	259	33
Buspirone Hcl	Buspirone Hcl	239	25
Fluticasone Propionate	Fluticasone Propionate	227	98
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	215	59
Amoxicillin	Amoxicillin	213	118
Metoprolol Succinate	Metoprolol Succinate	211	20
Rosuvastatin Calcium	Rosuvastatin Calcium	207	47
Hydrochlorothiazide	Hydrochlorothiazide	203	24
Tizanidine Hcl	Tizanidine Hcl	195	30
Escitalopram Oxalate	Escitalopram Oxalate	192	suppressed
Glipizide	Glipizide	188	38
Fenofibrate	Fenofibrate Nanocrystallized	186	27
Atenolol	Atenolol	185	30
Diclofenac Sodium	Diclofenac Sodium	184	64
Risperidone	Risperidone	183	suppressed
Labetalol Hcl	Labetalol Hcl	176	20
Prednisone	Prednisone	170	47
Finasteride	Finasteride	164	suppressed
Linzess	Linaclotide	163	37
Farxiga	Dapagliflozin Propanediol	155	24
Glimepiride	Glimepiride	154	30
Citalopram Hbr	Citalopram Hydrobromide	153	suppressed
Sertraline Hcl	Sertraline Hcl	145	suppressed
Azithromycin	Azithromycin	142	92
Meloxicam	Meloxicam	141	63
Simvastatin	Simvastatin	141	28
Nifedipine Er	Nifedipine	133	20
Tramadol Hcl	Tramadol Hcl	128	43
Duloxetine Hcl	Duloxetine Hcl	123	suppressed
Montelukast Sodium	Montelukast Sodium	123	17
Digoxin	Digoxin	121	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	121	52
Metoclopramide Hcl	Metoclopramide Hcl	119	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	115	suppressed
Benztropine Mesylate	Benztropine Mesylate	114	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	114	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	113	22
Spironolactone	Spironolactone	111	16
Oxycodone Hcl	Oxycodone Hcl	110	16
Fluoxetine Hcl	Fluoxetine Hcl	109	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	108	73
Olmesartan Medoxomil	Olmesartan Medoxomil	107	27
Oxybutynin Chloride	Oxybutynin Chloride	102	suppressed
Warfarin Sodium	Warfarin Sodium	102	suppressed
Sucralfate	Sucralfate	99	suppressed
Levofloxacin	Levofloxacin	97	53
Ropinirole Hcl	Ropinirole Hcl	97	15
Alprazolam	Alprazolam	95	suppressed
Ozempic	Semaglutide	95	17
Doxazosin Mesylate	Doxazosin Mesylate	94	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	94	19
Promethazine Hcl	Promethazine Hcl	93	26
Tradjenta	Linagliptin	93	11
Pregabalin	Pregabalin	92	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	88	20
Amitriptyline Hcl	Amitriptyline Hcl	86	suppressed
Ventolin Hfa	Albuterol Sulfate	86	23
Glipizide Er	Glipizide	85	13
Valsartan	Valsartan	83	suppressed
Paroxetine Hcl	Paroxetine Hcl	82	16
Ondansetron Hcl	Ondansetron Hcl	81	38
Oxybutynin Chloride Er	Oxybutynin Chloride	78	suppressed
Xarelto	Rivaroxaban	72	suppressed
Levemir Flexpen	Insulin Detemir	71	suppressed
Humalog Kwikpen U-100	Insulin Lispro	69	14
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	68	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	67	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	67	14
Symbicort	Budesonide/Formoterol Fumarate	65	14
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	64	14
Phenytoin	Phenytoin	64	suppressed
Oxcarbazepine	Oxcarbazepine	63	suppressed
Baclofen	Baclofen	62	suppressed
Celecoxib	Celecoxib	60	15
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	58	suppressed
Lamotrigine	Lamotrigine	58	suppressed
Midodrine Hcl	Midodrine Hcl	57	suppressed
Amiodarone Hcl	Amiodarone Hcl	56	suppressed
Pentoxifylline	Pentoxifylline	53	suppressed
Propranolol Hcl Er	Propranolol Hcl	52	suppressed
Thioridazine Hcl	Thioridazine Hcl	52	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	51	suppressed
Doxepin Hcl	Doxepin Hcl	51	suppressed
Fluconazole	Fluconazole	51	25
Lubiprostone	Lubiprostone	51	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	50	12
Bethanechol Chloride	Bethanechol Chloride	47	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	47	suppressed
Meclizine Hcl	Meclizine Hcl	45	13
Alendronate Sodium	Alendronate Sodium	44	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	44	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	42	23
Lactulose	Lactulose	41	11
Bumetanide	Bumetanide	39	suppressed
Cephalexin	Cephalexin	39	27
Bupropion Hcl	Bupropion Hcl	38	suppressed
Clindamycin Hcl	Clindamycin Hcl	38	25
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	38	suppressed
Methylprednisolone	Methylprednisolone	36	23
Primidone	Primidone	35	suppressed
Topiramate	Topiramate	35	suppressed
Unifine Safecontrol Pen Needle	Pen Needle,dual Safety,diabetc	35	11
Methocarbamol	Methocarbamol	34	11
Tolterodine Tartrate Er	Tolterodine Tartrate	32	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	31	24
Januvia	Sitagliptin Phosphate	31	suppressed
Ondansetron Odt	Ondansetron	31	24
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	30	suppressed
Dropsafe Pen Needle	Pen Needle, Diabetic, Safety	28	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	27	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	27	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	26	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	26	suppressed
Lacosamide	Lacosamide	26	suppressed
Novolog Flexpen	Insulin Aspart	26	suppressed
Scopolamine	Scopolamine	26	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	25	suppressed
Eszopiclone	Eszopiclone	24	suppressed
Insulin Aspart Flexpen	Insulin Aspart	24	suppressed
Nitroglycerin	Nitroglycerin	24	suppressed
Novolog Mix 70-30	Insulin Aspart Prot/Insuln Asp	24	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	23	15
Azelastine Hcl	Azelastine Hcl	22	11
Myrbetriq	Mirabegron	22	suppressed
Synthroid	Levothyroxine Sodium	22	suppressed
Latanoprost	Latanoprost	21	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	21	suppressed
Albuterol Sulfate	Albuterol Sulfate	20	suppressed
Bupropion Xl	Bupropion Hcl	20	suppressed
Chlorthalidone	Chlorthalidone	20	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	20	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Solifenacin Succinate	Solifenacin Succinate	20	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Cyproheptadine Hcl	Cyproheptadine Hcl	19	13
Methimazole	Methimazole	19	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	19	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	18	suppressed
Colchicine	Colchicine	18	11
Dapagliflozin	Dapagliflozin Propanediol	18	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	18	15
Vascepa	Icosapent Ethyl	18	suppressed
Ibuprofen	Ibuprofen	17	11
Piroxicam	Piroxicam	17	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	17	suppressed
Diazepam	Diazepam	16	suppressed
Metformin Hcl Er	Metformin Hcl	16	suppressed
Methotrexate	Methotrexate Sodium	16	suppressed
Nystatin	Nystatin	16	suppressed
Oseltamivir Phosphate	Oseltamivir Phosphate	16	15
Colesevelam Hcl	Colesevelam Hcl	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	15	suppressed
Naproxen	Naproxen	15	11
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	15	suppressed
Sulfasalazine	Sulfasalazine	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Carisoprodol	Carisoprodol	14	suppressed
Felodipine Er	Felodipine	14	suppressed
Folic Acid	Folic Acid	14	suppressed
Megestrol Acetate	Megestrol Acetate	14	suppressed
Metolazone	Metolazone	14	suppressed
Novolog	Insulin Aspart	14	suppressed
Calcitriol	Calcitriol	13	suppressed
Insulin Aspart	Insulin Aspart	13	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	13	suppressed
Torsemide	Torsemide	13	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	12	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Indomethacin	Indomethacin	12	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	suppressed
Temazepam	Temazepam	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Glyburide-Metformin Hcl	Glyburide/Metformin Hcl	11	suppressed
Humalog	Insulin Lispro	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Theophylline Er	Theophylline Anhydrous	11	suppressed
Veltassa	Patiromer Calcium Sorbitex	11	suppressed
Verapamil Hcl	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$86.43 · 4 records	AstraZeneca Pharmaceuticals LP	FARXIGA, OTEZLA, Ohtuvayre, REPATHA, TRELEGY ELLIPTA	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Farxiga play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error